[Sinovac Commences Phase III Clinical Trials for COVID-19 Vaccine Candidate in Turkey Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that it has recently commenced phase III clinical trials for its inactivate]
[Sinovac Commences Phase III Clinical Trials for COVID-19 Vaccine Candidate in Turkey Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that it has recently commenced phase III clinical trials for its inactivate]
[SCHEDULE 13G/A (Amendment No. 3)* Renren Inc. (Name of Issuer) Class A Ordinary Shares, par value US$0.001 per share (Title of Class of Securities) 759892300** (CUSIP Number) June 19, 2020 (Date of event which requires filing of this statement) ☐ Rule 13d-1(b) ☒ Rule 13d-1(c) ☐ Rule 13d-1(d) (Page 1]
[SCHEDULE 13G/A (Amendment No. 3)* Renren Inc. (Name of Issuer) Class A Ordinary Shares, par value US$0.001 per share (Title of Class of Securities) 759892300** (CUSIP Number) June 19, 2020 (Date of event which requires filing of this statement) ☐ Rule 13d-1(b) ☒ Rule 13d-1(c) ☐ Rule 13d-1(d) (Page 1]
[SGOCO Group, Ltd. Appoints New Director The Company today announced that the Board of Directors of the Company has appointed Mr. Mark Leonard Tan (“Mr. Tan”) as the director of the Company, effective on September 23, 2020 to replace Mr. Hok Fung Wai who notified his resignation from the Board, effec]
[SGOCO Group, Ltd. Appoints New Director The Company today announced that the Board of Directors of the Company has appointed Mr. Mark Leonard Tan (“Mr. Tan”) as the director of the Company, effective on September 23, 2020 to replace Mr. Hok Fung Wai who notified his resignation from the Board, effec]
